In the first of a two part series on chimeric antigen receptor (CAR) cells, we take a look at some novel developments, not all of which are T cell based.

Can switchable CARs make a lasting impact?

Increasingly researchers are exploring the potential for novel approaches with other immune cells, as well as ways to potentially make cell therapies safer for patients using switchable technology.

What’s the skinny on these approaches and do they have some legs for the long term?

Here we take a look at some innovative ideas which caught our attention – not all of which may have a long term future…

To learn more about our ongoing post AACR21 reviews and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by